Title: Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma
Authors: Matulonis, Ursula ×
Vergote, Ignace
Backes, Floor
Martin, Lainie P
McMeekin, Scott
Birrer, Michael
Campana, Frank
Xu, Yi
Egile, Coumaran
Ghamande, Sharad #
Issue Date: Feb-2015
Publisher: Academic Press
Series Title: Gynecologic Oncology vol:136 issue:2 pages:246-53
Article number: S0090-8258(14)01574-1
Abstract: Patients with endometrial carcinoma who progress after first-line chemotherapy have a poor prognosis. Phosphoinositide 3-kinase (PI3K) inhibitors are investigational treatment options in this setting. This study evaluated the efficacy and safety of the PI3K inhibitor pilaralisib (SAR245408; XL147) in advanced or recurrent endometrial carcinoma.
ISSN: 0090-8258
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Non-KU Leuven Association publications
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science